Biosimilar Newsletter Archive

  1. 09.11.24 -- All Eyes On Sustainability 9/11/2024

    09/11/24 Biosimilar Development Newsletter

  2. 09.05.24 -- Why Pharma 4.0 May Not Be Optional For Much Longer 9/5/2024
    09/05/24 Biosimilar Development Newsletter
  3. 08.29.24 -- Wearable Injectors: An Alternative To Traditional Intravenous Administration 8/29/2024
    08/29/24 Biosimilar Development Newsletter
  4. 08.28.24 -- Evolving Design Space Requirements For Biologic Combination Products 8/28/2024

    08/28/24 Biosimilar Development Newsletter

  5. 08.22.24 -- Draft Guidance Offers Biosimilar Post-Approval Change Roadmap 8/22/2024
    08/22/24 Biosimilar Development Newsletter
  6. 08.15.24 -- Your Molecule May Be Ready, But What About Your Device? 8/15/2024

    08/15/24 Biosimilar Development Newsletter

  7. 08.15.24 -- Harnessing Analytics To Minimize Antibody Variants 8/15/2024
    08/15/24 Biosimilar Development Newsletter
  8. 08.08.24 -- The Biosimilars Forum Supports House Committee Probe Into The PBM Monopoly 8/8/2024
    08/08/24 Biosimilar Development Newsletter
  9. 08.05.24 -- Explore The Benefits Of Outsourcing To A Polish CDMO 8/5/2024

    08/05/24 Biosimilar Development Newsletter

  10. 08.01.24 -- Sandoz Launches Biosimilar Pyzchiva Across Europe 8/1/2024
    08/01/24 Biosimilar Development Newsletter